New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2013
04:55 EDTALKS, ALKS, ANGO, ANGO, SNSS, SNSS, VHS, VHS, IART, IART, OCR, OCR, BKD, BKD, BAX, BAX, ARIA, ARIARBC Capital to host a conference
Healthcare Conference is being held in New York on February 26-27.
News For ALKS;ANGO;SNSS;VHS;IART;OCR;BKD;BAX;ARIA From The Last 14 Days
Check below for free stories on ALKS;ANGO;SNSS;VHS;IART;OCR;BKD;BAX;ARIA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 2, 2014
07:12 EDTALKSCredit Suisse names its Top U.S. Pharmaceutical picks for 2H
Subscribe for More Information
06:09 EDTSNSSStocks with implied volatility movement; SNNS SM
Stocks with implied volatility movement; Sunesis (SNNS) 284, SM Energy (SM) 33 according to iVolatility.
August 31, 2014
13:23 EDTBAXGoldman to hold a conference
Subscribe for More Information
August 29, 2014
10:18 EDTSNSSOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:01 EDTSNSSSunesis downgraded to Neutral from Outperform at Wedbush
Wedbush downgraded Sunesis citing valuation.
06:14 EDTSNSSSunesis implied volatility of 255 at upper end of index mean range
Subscribe for More Information
August 28, 2014
08:14 EDTBKDJefferies to hold a bus tour
Subscribe for More Information
06:31 EDTSNSSSunesis volatility increases on price movement
Subscribe for More Information
August 27, 2014
16:28 EDTSNSSOn The Fly: Closing Wrap
Subscribe for More Information
15:41 EDTSNSSSunesis rises ahead of critical trial data
Subscribe for More Information
09:08 EDTBAXNektar could see $100M in revenue from Baxter drug, says Roth Capital
Roth Capital believes that Baxter's (BAX) BAX-855 drug delivered compelling Phase III data, and the firm expects the drug to compete effectively against Biogen's (BIIB) Eloctate. Roth expects BAX-855 to launch in 1Q16 and believes it could generate up to $100M in annual revenue for Nektar. The firm keeps a $21 price target and Buy rating on Nektar.
07:56 EDTSNSSStreet too cautious about upcoming Sunesis VALOR data, says UBS
Subscribe for More Information
August 26, 2014
07:05 EDTALKSAlkermes initiates Phase 1 clinical study of ALKS 7106 for treatment of pain
Subscribe for More Information
August 25, 2014
12:37 EDTARIAARIAD ICLUSIG prescriptions encouraging, says BMO Capital
Subscribe for More Information
10:40 EDTARIABiotechs rise after InterMune acquired by Roche
Subscribe for More Information
07:59 EDTBKDSome healthcare providers offer compelling opportunities, says Jefferies
Jefferies believes that the following healthcare providers reported good Q2 results which have not been adequately reflected by their stocks: Acadia Healthcare (ACHC), Almost Family (AFAM), Brookdale Senior Living (BKD), Catamaran (CTRX), Community Health (CYH), Envision Healthcare (EVHC), and HCA Holdings (HCA). The firm expects the sector as a whole to continue to improve in 2H14 amid continued tailwinds from healthcare reform.
07:01 EDTALKSAlkermes submits NDA to FDA for aripiprazole lauroxil
Subscribe for More Information
August 24, 2014
21:54 EDTIARTPiper Jaffray to hold a bus tour
Subscribe for More Information
August 21, 2014
15:37 EDTBAXNektar: Baxter announces positive results from Phase 3 study of BAX 855
Nektar Therapeutics (NKTR) reports Baxter International (BAX) announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII treatment for hemophilia A based on ADVATE, which met its primary endpoint in reducing annualized bleed rates in the prophylaxis arm compared to the on-demand arm. Top-line results from the prospective, global, multi-center Phase 3 study demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding, routine prophylaxis and perioperative management for patients who were 12 years or older. Patients in a twice-weekly prophylaxis arm experienced a 95 percent reduction in median ABR as compared to those in the on-demand arm (1.9 vs. 41.5, respectively). BAX 855 was also effective in treating bleeding episodes, 96 percent of which were controlled with one or two infusions. The half-life of BAX 855 was 1.4 - 1.5 times that of ADVATE, consistent with the findings from the Phase 1 study. No patients developed inhibitors to BAX 855 and no treatment-related serious adverse events, including hypersensitivity, were reported. The most common product-related adverse event was headache. Baxter expects to submit a Biologics License Application for BAX 855 to the U.S. Food and Drug Administration before the end of 2014 and will present additional data in the coming months. In addition to an ongoing continuation study for patients who have completed the pivotal trial, the company is initiating a Phase 3, prospective, open-label, multi-center study to evaluate the safety and efficacy of BAX 855 among 60 previously treated patients under the age of 12 with severe hemophilia A. Consistent with guidelines published by the European Medicines Agency that require a study in children less than 12 years of age prior to filing, Baxter expects to file a Marketing Authorization Application with the EMA upon the completion of the pediatric study
09:02 EDTBAXBaxter announces BAX 855 met primary endpoint in Phase 3 study
Baxter announced "positive" results from its Phase 3 pivotal clinical trial of BAX 855, which met its primary endpoint in reducing annualized bleed rates in the prophylaxis arm compared to the on-demand arm. Top-line results from the prospective, global, multi-center Phase 3 study demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding, routine prophylaxis and perioperative management for patients who were 12 years or older. Patients in a twice-weekly prophylaxis arm experienced a 95% reduction in median ABR as compared to those in the on-demand arm. BAX 855 was also effective in treating bleeding episodes, 96% of which were controlled with one or two infusions. The half-life of BAX 855 was 1.4 1.5 times that of ADVATE, consistent with the findings from the Phase 1 study. No patients developed inhibitors to BAX 855 and no treatment-related serious adverse events, including hypersensitivity, were reported. The most common product-related adverse event was headache. Baxter expects to submit a Biologics License Application for BAX 855 to the U.S. Food and Drug Administration before the end of 2014 and will present additional data in the coming months. In addition to an ongoing continuation study for patients who have completed the pivotal trial, the company is initiating a Phase 3, prospective, open-label, multi-center study to evaluate the safety and efficacy of BAX 855 among 60 previously treated patients under the age of 12 with severe hemophilia A. Consistent with guidelines published by the European Medicines Agency that require a study in children less than 12 years of age prior to filing, Baxter expects to file a Marketing Authorization Application with the EMA upon the completion of the pediatric study.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use